A case of irinotecan or panitumumab-induced interstitial pneumonia successfully treated by steroid pulse therapy

Japanese Journal of Cancer and Chemotherapy

Volumn 39, Issue 2, 2012, Pages 305-309

  Yamamoto, Kenta ^a   Kato, Toshio ^a   Shindo, Jo ^a   Ando, Morihide ^a   Abe, Takashi ^a   Shiraki, Akira ^a   Nakashima, Harunori ^a   Yukita, Yosuke ^a  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Interstitial pneumonitis; Irinotecan; Panitumumab

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHYLPREDNISOLONE; OXALIPLATIN; PANITUMUMAB;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTERSTITIAL PNEUMONIA; MALE; MULTIPLE CYCLE TREATMENT; SIGMOIDECTOMY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG DISEASES, INTERSTITIAL; MALE; METHYLPREDNISOLONE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84860514501     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Biotherapy 24(5): 408-411, 2010.
2. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10): 1626-1634, 2008.
3. Giusti RM, Shastri KA, Cohen MH, et al: FDA drug approval summary:panitumumab (Vectibix™). Oncologist 12(5): 577-583, 2007.
4. Nurse eye 20(4): 89-93, 2007.
5. Nurse eye 21(2): 82-87, 2008.
6. Okamoto I, Fujii K, Matsumoto M, et al: Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell cancer. Lung Cancer 40(3): 339-342, 2003.